LALPATHLAB1,912.00

Dr. Lal Path Labs Ltd.

· Pharma & Health
₹ CrorePeersMETROPOLISVIJAYATHYROCARENATCOPHARMNEULANDLABNHCOHANCESAILIFEMcap ₹32,045 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation143.6141.9161.8
+ Impairment Loss / (Reversal)0.03.40.0
+ Finance Costs29.422.322.8
+ Interest Income-55.4-66.5-67.0
+ Fair Value (Gains) / Losses-10.40.0-19.4
+ Share-based Payments21.727.223.8
+ Unrealised FX (Gain) / Loss-0.20.00.2
+ Other Non-cash Items-0.50.00.0
+ Other — Cash Effects are Investing / Financing0.00.0-11.7
+ Other Reconciling Items-2.0-26.34.9
Changes in Working Capital
+ Inventories-3.51.2-7.7
+ Trade Receivables — Current-7.3-15.3-26.8
+ Other Financial Assets — Current1.8-0.9-0.8
+ Other Financial Assets — Non-current0.00.0-2.7
+ Other Current Assets-3.9-2.60.6
+ Trade Payables — Current30.512.313.5
+ Other Financial Liabilities — Current6.14.05.5
+ Other Current Liabilities3.38.1-1.0
+ Provisions — Current8.7-0.846.0
Cash from Operating Activities
Profit Before Tax (per I/S)505.5624.7669.1716.7
+ Total Adjustments (incl. Working Capital)161.9108.0142.0
Cash from Operations (pre-tax)667.4732.7811.1
+ Income Taxes Paid132.0163.9175.4
Cash from Operating Activities535.4568.8635.7
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)51.244.3167.0
+ Acq of Intangible Assets6.39.66.4
+ Disp of Fixed Assets0.90.70.5
+ Acq of Subsidiaries / Businesses (net)0.40.00.0
+ Interest Received — Investing45.363.166.4
+ Other Inflows / (Outflows) — Investing-12.6-313.0-315.4
Cash from Investing Activities-24.3-303.1-421.9
Cash from Financing Activities
+ Proceeds from Issue of Shares0.012.718.6
+ Proceeds from Exercise of Stock Options3.50.00.0
+ Repayment of Borrowings153.383.30.0
+ Payment of Lease Liabilities33.533.836.8
+ Interest Paid29.422.322.8
+ Dividends Paid201.2207.3222.6
Cash from Financing Activities-413.9-334.0-263.6
Net Changes in Cash (pre-FX)97.2-68.3-49.8
Net Changes in Cash97.2-68.3-49.8
Closing Cash360.9292.6242.8
Reference Items
EBITDA609.3695.5782.5837.7
EBITDA Margin %27.3628.2628.3228.98
Free Cash Flow (CFO − Capex)477.9514.9462.3462.3
Free Cash Flow to Equity409.3439.5
Free Cash Flow per Basic Share28.5130.7227.5827.58
Price to Free Cash Flow69.32
Cash Flow to Net Income1.481.161.25
Cash Paid for Taxes132.0163.9175.4
Cash Paid for Interest29.422.322.8
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.